Skip to content

Clinical End Points in Coronary Stent Trials

Donald E. Cutlip, Stephan Windecker, Roxana Mehran, Ashley B. Boam, David J. Cohen, Gerrit‐Anne van Es, Philippe Gabríel Steg, Marie‐Angèle Morel, Laura Mauri, Pascal Vranckx, Eugene Patrick McFadden, Alexandra J. Lansky, Martial Hamon, Mitchell W. Krucoff, Patrick W.J.C. Serruys

Circulation · 2007 · 5,502 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Cutlip, D. E., Windecker, S., Mehran, R., Boam, A. B., Cohen, D. J., Es, G. van, Steg, P. G., Morel, M., Mauri, L., Vranckx, P., McFadden, E. P., Lansky, A. J., Hamon, M., Krucoff, M. W., & Serruys, P. W. (2007). Clinical end points in coronary stent trials. Circulation, 115(17), 2344–2351. https://doi.org/10.1161/circulationaha.106.685313

In text: (Cutlip et al., 2007)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: Although most clinical trials of coronary stents have measured nominally identical safety and effectiveness end points, differences in definitions and timing of assessment have created confusion in interpretation. METHODS AND RESULTS: The Academic Research Consortium is an informal collaboration between academic research organizations in the United States and Europe. Two meetings, in Washington, DC, in January 2006 and in Dublin, Ireland, in June 2006, sponsored by the Academic Research Consortium and including representatives of the US Food and Drug Administration and all device manufacturers who were working with the Food and Drug Administration on drug-eluting stent clinical trial programs, were focused on consensus end point definitions for drug-eluting stent evaluations. The effort was pursued with the objective to establish consistency among end point definitions and provide consensus recommendations. On the basis of considerations from historical legacy to key pathophysiological mechanisms and relevance to clinical interpretability, criteria for assessment of death, myocardial infarction, repeat revascularization, and stent thrombosis were developed. The broadly based consensus end point definitions in this document may be usefully applied or recognized for regulatory and clinical trial purposes. CONCLUSION: Although consensus criteria will inevitably include certain arbitrary features, consensus criteria for clinical end points provide consistency across studies that can facilitate the evaluation of safety and effectiveness of these devices.

  1. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study2004
  2. Tissue Plasminogen Activator for Acute Ischemic Stroke1995
  3. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation2017
  4. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association2019
  5. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.1986

Metadata from OpenAlex (CC0). Citations are generated from the published record.